Last reviewed · How we verify

NCT05343507

Ketamine to Treat Patients With Post-comatose Disorders of Consciousness

Recruiting now Phase 2, PHASE3 Last updated 7 November 2022
What this trial tests

Phase 2, PHASE3 trial testing Ketalar 50 MG/ML Injectable Solution in Disorder of Consciousness in 30 participants. Currently enrolling.

Timeline
1 May 2022
Primary endpoint
1 May 2025
1 May 2026

Quick facts

Lead sponsorUniversity of Liege
PhasePhase 2, PHASE3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposetreatment
Enrollment30
Start date1 May 2022
Primary completion1 May 2025
Estimated completion1 May 2026
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

University of Liege

Who can join

Adults 18 to 65, any sex, with Disorder of Consciousness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will run a Randomized Clinical Trial with 30 patients with disorders of consciousness (DoC), with intravenous subanesthetic doses of ketamine. Patients will simultaneously undergo TMS-EEG. The piloting will be done on 3 patients, with EEG only.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Restoring consciousness with pharmacologic therapy: Mechanisms, targets, and future directions.
    Barra ME, Solt K, Yu X, Edlow BL. · · 2024 · cited 11× · PMID 39019729 · DOI 10.1016/j.neurot.2024.e00374

Verify or expand the search:

Other trials of Ketalar 50 MG/ML Injectable Solution

Trials testing the same drug.

Other recruiting trials for Disorder of Consciousness

Currently open trials in the same condition.

Other University of Liege trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05343507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing